Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A Deep Learning-Based Approach to Reduce Rescan and Recall Rates in Clinical MRI Examinations.

Sreekumari A, Shanbhag D, Yeo D, Foo T, Pilitsis J, Polzin J, Patil U, Coblentz A, Kapadia A, Khinda J, Boutet A, Port J, Hancu I.

AJNR Am J Neuroradiol. 2019 Jan 3. doi: 10.3174/ajnr.A5926. [Epub ahead of print]

PMID:
30606726
2.

Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice.

Cataldi S, Follett J, Fox JD, Tatarnikov I, Kadgien C, Gustavsson EK, Khinda J, Milnerwood AJ, Farrer MJ.

NPJ Parkinsons Dis. 2018 Aug 21;4:27. doi: 10.1038/s41531-018-0063-3. eCollection 2018.

3.

Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice.

Volta M, Beccano-Kelly DA, Paschall SA, Cataldi S, MacIsaac SE, Kuhlmann N, Kadgien CA, Tatarnikov I, Fox J, Khinda J, Mitchell E, Bergeron S, Melrose H, Farrer MJ, Milnerwood AJ.

Elife. 2017 Sep 20;6. pii: e28377. doi: 10.7554/eLife.28377.

4.

DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.

Trinh J, Gustavsson EK, Vilariño-Güell C, Bortnick S, Latourelle J, McKenzie MB, Tu CS, Nosova E, Khinda J, Milnerwood A, Lesage S, Brice A, Tazir M, Aasly JO, Parkkinen L, Haytural H, Foroud T, Myers RH, Sassi SB, Hentati E, Nabli F, Farhat E, Amouri R, Hentati F, Farrer MJ.

Lancet Neurol. 2016 Nov;15(12):1248-1256. doi: 10.1016/S1474-4422(16)30203-4. Epub 2016 Sep 28.

PMID:
27692902
5.

DCTN1 p.K56R in progressive supranuclear palsy.

Gustavsson EK, Trinh J, Guella I, Szu-Tu C, Khinda J, Lin CH, Wu RM, Stoessl J, Appel-Cresswell S, McKeown M, Rajput A, Rajput AH, Petersen MS, Jeon BS, Aasly JO, Farrer MJ.

Parkinsonism Relat Disord. 2016 Jul;28:56-61. doi: 10.1016/j.parkreldis.2016.04.025. Epub 2016 Apr 23.

PMID:
27132499
6.

Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.

Volta M, Cataldi S, Beccano-Kelly D, Munsie L, Tatarnikov I, Chou P, Bergeron S, Mitchell E, Lim R, Khinda J, Lloret A, Bennett CF, Paradiso C, Morari M, Farrer MJ, Milnerwood AJ.

Parkinsonism Relat Disord. 2015 Oct;21(10):1156-63. doi: 10.1016/j.parkreldis.2015.07.025. Epub 2015 Aug 1.

PMID:
26282470
7.

Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.

Munsie LN, Milnerwood AJ, Seibler P, Beccano-Kelly DA, Tatarnikov I, Khinda J, Volta M, Kadgien C, Cao LP, Tapia L, Klein C, Farrer MJ.

Hum Mol Genet. 2015 Mar 15;24(6):1691-703. doi: 10.1093/hmg/ddu582. Epub 2014 Nov 21.

PMID:
25416282
8.

Endovascular intervention in renovascular disease: a pictorial review.

Khinda J, Athreya S.

Insights Imaging. 2014 Dec;5(6):667-76. doi: 10.1007/s13244-014-0363-z. Epub 2014 Oct 12.

9.

Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.

Walker MD, Volta M, Cataldi S, Dinelle K, Beccano-Kelly D, Munsie L, Kornelsen R, Mah C, Chou P, Co K, Khinda J, Mroczek M, Bergeron S, Yu K, Cao LP, Funk N, Ott T, Galter D, Riess O, Biskup S, Milnerwood AJ, Stoessl AJ, Farrer MJ, Sossi V.

J Parkinsons Dis. 2014;4(3):483-98. doi: 10.3233/JPD-140344.

PMID:
25000966

Supplemental Content

Loading ...
Support Center